Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2016-12-13 Regulatory Filings
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Approved Admission Document
Regulatory Filings Classification · 95% confidence The document is titled 'Approved Admission Document' and explicitly states it was prepared 'in connection with the admission to trading on Merkur Market on December 14, 2016.' This type of document, related to listing on an exchange, does not fit the primary definitions (10-K, IR, ER, etc.). Since it is a specific regulatory/listing document that doesn't fit the other categories, and it is very short (434 chars) and points to an attachment ('See attachment at www.newsweb.no'), it is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) due to the listing context. Given the lack of specific financial reporting or management changes, RNS serves as the most appropriate general regulatory fallback for an admission document.
2016-12-13 English
Oslo Børs - GENT-ME - New company admitted to trading on Merkur Market 14.12.2016
Regulatory Filings Classification · 95% confidence The document text is very short (727 characters) and announces that a new company, Gentian Diagnostics AS, is being admitted to trading on the Merkur Market (a segment of Oslo Børs). This is a specific corporate action related to listing/trading status, not a standard periodic financial report (like 10-K or IR) or a management change. It does not fit perfectly into the defined categories like DIV, DIRS, or ER. Since it is a specific regulatory announcement regarding the listing/trading of shares, and it is not a general financial report, the most appropriate fallback category is Regulatory Filings (RNS), as it is a formal notice to the market about a change in the security's status.
2016-12-13 English
Oslo Børs - Received application for admission to trading on Merkur Market
Regulatory Filings Classification · 100% confidence The document text is very short (403 characters) and announces that Oslo Børs has received an application for admission to trading for Gentian Diagnostics AS on Merkur Market, with an expected admission date of December 14, 2016. This is a specific regulatory announcement concerning the listing status of a company's shares, but it does not fit neatly into the defined categories like Capital Change (SHA), Delisting (DLST), or a standard financial report. Given the nature of the announcement (a market/exchange notification that doesn't fit the specific financial/governance codes), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements.
2016-12-13 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.